These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9239917)

  • 1. [Oral vasodilators in the treatment of congestive heart failure].
    Pérez-Olea J
    Rev Med Chil; 1996 Oct; 124(10):1256-60. PubMed ID: 9239917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin-converting enzyme inhibitors.
    Chow MS
    Pharmacotherapy; 1993; 13(5 Pt 2):82S-87S. PubMed ID: 8233997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasodilator therapy for congestive heart failure. Lessons from mortality trials.
    Groden DL
    Arch Intern Med; 1993 Feb; 153(4):445-54. PubMed ID: 8435024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
    Gradman AH; Alfayoumi F
    Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The treatment of cardiac insufficiency with vasodilators].
    Biollaz J; Munafo A
    Schweiz Med Wochenschr; 1988 Apr; 118(17):616-20. PubMed ID: 3381076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors of asymptomatic first-dose hypotension with angiotensin-converting enzyme inhibitors in chronic heart failure due to systolic dysfunction.
    Thanikachalam S; Manchanda SC
    Indian Heart J; 2003; 55(2):167-71. PubMed ID: 12921333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Heart failure due to diastolic dysfunction: the treatment principles].
    Pinamonti B; di Lenarda A; Sinagra G
    Ital Heart J Suppl; 2000 Apr; 1(4):469-80. PubMed ID: 10832133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Trends in pharmacological treatment of congestive heart failure].
    Halawa B
    Pol Merkur Lekarski; 1999 Mar; 6(33):152-6. PubMed ID: 10365602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New oral drugs for the treatment of congestive heart failure].
    Hayashida W; Kumada T; Kawai C
    Nihon Rinsho; 1992 Feb; 50(2):413-9. PubMed ID: 1319514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of congestive heart failure. II. Vasodilators and angiotensin-converting enzyme inhibitors.
    Aronow WS
    Ration Drug Ther; 1982 Oct; 16(10):1-5. PubMed ID: 6294740
    [No Abstract]   [Full Text] [Related]  

  • 12. Patterns of physician use of angiotensin converting enzyme inhibitors in the inpatient treatment of congestive heart failure.
    Ghali JK; Giles T; Gonzales M; Horswell R; Kumar S; Lejuene A; Livaudais GF; Sarkar IC
    J La State Med Soc; 1997 Dec; 149(12):474-84. PubMed ID: 9425858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of vasodilator treatment in beginning cardiac insufficiency].
    Vacheron A
    Bull Acad Natl Med; 1989 Jan; 173(1):51-5; discussion 55-6. PubMed ID: 2765989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuro-hormonal mechanisms in heart failure -- from physiopathology to treatment].
    Cerqueira-Gomes M; Polónia J; Brandão F; Ramalhão C; da Faria DB
    Rev Port Cardiol; 2001 May; 20 Suppl 5():V-99-122; discussion V-123-5. PubMed ID: 11515306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving rationale for angiotensin-converting enzyme inhibition in chronic heart failure.
    Banerjee A; Talreja A; Sonnenblick EH; LeJemtel TH
    Mt Sinai J Med; 2003 Sep; 70(4):225-31. PubMed ID: 12968195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R; McMurray JJ
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: a review. III. Angiotensin-converting enzyme inhibitors.
    Ascenção R; Fortuna P; Reis I; Carneiro AV
    Rev Port Cardiol; 2008 Sep; 27(9):1169-87. PubMed ID: 19044179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of diastolic heart failure--a practical review of pathophysiology and treatment trial data.
    Wu EB; Yu CM
    Int J Clin Pract; 2005 Oct; 59(10):1239-46. PubMed ID: 16178994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
    Aronow WS
    J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.